Get the Stockscreener App
1.97
4.79%
0.09
After Hours:
1.97
Milestone Pharmaceuticals Inc stock is traded at $1.97, with a volume of 1.36M.
It is up +4.79% in the last 24 hours and up +29.61% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
See More
Previous Close:
$1.88
Open:
$1.91
24h Volume:
1.36M
Relative Volume:
0.67
Market Cap:
$235.69M
Revenue:
$1.55M
Net Income/Loss:
$-63.06M
P/E Ratio:
-2.4752
EPS:
-0.7959
Net Cash Flow:
$-49.45M
1W Performance:
+8.24%
1M Performance:
+29.61%
6M Performance:
+14.53%
1Y Performance:
+53.91%
1-Day Range:
$1.88
$2.02
1-Week Range:
$1.765
$2.02
52-Week Range:
$1.00
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.97 | 224.92M | 1.55M | -63.06M | -49.45M | -0.7959 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Upgrade | TD Cowen | Hold → Buy |
| Sep-11-25 | Initiated | Wells Fargo | Overweight |
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026 - The Manila Times
Milestone Pharmaceuticals gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
[DEF 14A] Milestone Pharmaceuticals Inc. Definitive Proxy Statement - Stock Titan
[ARS] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update - MarketBeat
MIST stock soars pre-market after FDA approves first commercial product – retail remains bullish, dismisses 'sell the news' concerns - MSN
MIST Technical Analysis | Trend, Signals & Chart Patterns | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Milestone (MIST) Business Update | Q4 2025: Below ExpectationsBlock Trade - Xã Thanh Hà
Milestone Pharmaceuticals (MIST) Proxy Filing Summary - Quartr
Insider Sell: Joseph Oliveto Sells 36,500 Shares of Milestone Ph - GuruFocus
Milestone (MIST) CEO sells 36,500 shares under Rule 10b5-1 plan - Stock Titan
Why Milestone Pharma stock is taking a dive today - MSN
[144] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
RSI Check: What are the risks of holding Milestone Pharmaceuticals Inc2026 Final Week & Growth Focused Stock Pick Reports - baoquankhu1.vn
Risk Check: Is Milestone Pharmaceuticals Inc a momentum stock2026 Investor Takeaways & Real-Time Volume Spike Alerts - baoquankhu1.vn
MIST: CARDAMYST launches with strong clinical data, broad provider targeting, and robust financial runway - TradingView
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone - Yahoo Finance
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded to Strong-Buy at Raymond James Financial - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Raymond James Financial Initiates Coverage on Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
Milestone Pharmaceuticals (MIST) Launches RESET-PSVT Study for C - GuruFocus
Milestone Pharmaceuticals plans real-world PSVT registry study By Investing.com - Investing.com Canada
Milestone Pharmaceuticals plans real-world PSVT registry study - Investing.com
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT - The Manila Times
Milestone Pharmaceuticals Announces Registry to Generate Real-World Evidence on Cardamyst Nasal Spray in Patients with Psvt - marketscreener.com
Raymond James initiates Milestone Pharmaceuticals stock coverage with Strong Buy - Investing.com
Raymond James initiates Milestone Pharmaceuticals stock coverage with Strong Buy By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST (etripamil) Nasal Spray in Patients With PSVT - Bitget
Milestone Pharmaceuticals Expands Market with Cardamyst Nasal Spray Inclusion - StocksToTrade
MARKING MAJOR MILESTONE OF 100,000 PATIENTS TREATED, NORDIC PHARMA, INC. (U.S.) ENHANCES ITS OFFERING AND INCREASES PROVIDER CONVENIENCE BY INCLUDING CANNULAS WITH ITS SHIPMENTS OF LACRIFILL® CANALICUL - PR Newswire
Gains Report: Can Milestone Pharmaceuticals Inc beat the S P 500IPO Watch & Consistent Income Trade Ideas - baoquankhu1.vn
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - Bitget
Will Freshworks Inc. stock benefit from sector rotationWeekly Profit Recap & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Will Milestone (MIST) Stock Rise in 2026 | Price at $1.46, Up 5.43%Community Chart Signals - Cổng thông tin điện tử tỉnh Lào Cai
Buybacks Report: Does Milestone Pharmaceuticals Inc offer margin of safetyMarket Activity Recap & Scalable Portfolio Growth Methods - baoquankhu1.vn
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Three new hires get 123,000 Milestone stock options under Nasdaq rule - Stock Titan
Institution Moves: Is Milestone Pharmaceuticals Inc undervalued by DCF analysis2026 Earnings Impact & Free Community Consensus Stock Picks - baoquankhu1.vn
Trails Edge Capital Partners, LP Acquires 5,333,333 Shares in Mi - GuruFocus
Milestone Pharmaceuticals Announces that CARDAMYST (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - Bitget
Milestone Pharmaceuticals (MIST) Secures Formulary Inclusion for Cardamyst - GuruFocus
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - The Manila Times
Express Scripts adds new PSVT nasal spray to national formularies - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):